T1	Disease	68 96	non-small cell lung cancer (
T2	Disease	97 114	NSCLC ) confirmed
T3	Pharmacodynamic_phenotype	128 145	response rate and
T4	Phenotype	146 174	progression-free survival of
T5	Gene_or_protein	181 248	epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor
T6	Chemical	181 257	epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor as first
T7	Chemical	285 309	chemotherapy in patients
T8	Limited_variation	341 342	.
R1	isEquivalentTo	Arg1:T1	Arg2:T2
R2	increases	Arg1:T1	Arg2:T3
R3	increases	Arg1:T1	Arg2:T4
R4	treats	Arg1:T1	Arg2:T8
R5	isEquivalentTo	Arg1:T2	Arg2:T1
R6	increases	Arg1:T2	Arg2:T3
R7	increases	Arg1:T2	Arg2:T4
R8	increases	Arg1:T3	Arg2:T4
R9	isAssociatedWith	Arg1:T3	Arg2:T5
R10	isAssociatedWith	Arg1:T3	Arg2:T7
R11	isAssociatedWith	Arg1:T3	Arg2:T8
R12	isAssociatedWith	Arg1:T4	Arg2:T1
R13	isAssociatedWith	Arg1:T4	Arg2:T2
R14	isAssociatedWith	Arg1:T4	Arg2:T3
R15	isAssociatedWith	Arg1:T4	Arg2:T5
R16	isAssociatedWith	Arg1:T4	Arg2:T6
R17	isAssociatedWith	Arg1:T4	Arg2:T7
R18	isAssociatedWith	Arg1:T4	Arg2:T8
R19	treats	Arg1:T5	Arg2:T1
R20	treats	Arg1:T5	Arg2:T2
R21	increases	Arg1:T5	Arg2:T3
R22	increases	Arg1:T5	Arg2:T4
R23	influences	Arg1:T5	Arg2:T6
R24	influences	Arg1:T5	Arg2:T7
R25	treats	Arg1:T5	Arg2:T8
R26	treats	Arg1:T6	Arg2:T1
R27	treats	Arg1:T6	Arg2:T2
R28	increases	Arg1:T6	Arg2:T3
R29	increases	Arg1:T6	Arg2:T4
R30	influences	Arg1:T6	Arg2:T5
R31	influences	Arg1:T6	Arg2:T7
R32	treats	Arg1:T6	Arg2:T8
R33	treats	Arg1:T7	Arg2:T1
R34	treats	Arg1:T7	Arg2:T2
R35	increases	Arg1:T7	Arg2:T3
R36	influences	Arg1:T7	Arg2:T5
R37	influences	Arg1:T7	Arg2:T6
R38	isAssociatedWith	Arg1:T7	Arg2:T8
R39	isAssociatedWith	Arg1:T8	Arg2:T1
R40	isAssociatedWith	Arg1:T8	Arg2:T2
R41	influences	Arg1:T8	Arg2:T3
R42	influences	Arg1:T8	Arg2:T4
R43	influences	Arg1:T8	Arg2:T5
R44	influences	Arg1:T8	Arg2:T6
R45	isAssociatedWith	Arg1:T8	Arg2:T7
